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L-carnitine, a nutrient in red meat, was recently
reported to accelerate atherosclerosis via a metaor-
ganismal pathway involving gut microbial trimethyl-
amine (TMA) formation and host hepatic conversion
into trimethylamine-N-oxide (TMAO). Herein, we
show that following L-carnitine ingestion, g-butyro-
betaine (gBB) is produced as an intermediary metab-
olite by gut microbes at a site anatomically proximal
to and at a rate1,000-fold higher than the formation
of TMA.Moreover, we show that gBB is themajor gut
microbial metabolite formed from dietary L-carnitine
in mice, is converted into TMA and TMAO in a gut mi-
crobiota-dependentmanner (like dietary L-carnitine),
and accelerates atherosclerosis. Gut microbial
composition and functional metabolic studies reveal
that distinct taxa are associated with the production
of gBB or TMA/TMAO from dietary L-carnitine. More-
over, despite their close structural similarity, chronic
dietary exposure to L-carnitine or gBB promotes
development of functionally distinct microbial com-
munities optimized for the metabolism of L-carnitine
or gBB, respectively.
INTRODUCTION
The past several years havewitnessed a growing awareness that
gut microbiota serve as active participants in the expression of
complex metabolic phenotypes, such as insulin resistance and
obesity (Ba¨ckhed et al., 2004; Cho et al., 2012; Karlsson et al.,
2013; Ley et al., 2005; Sayin et al., 2013). Animal model and hu-
man clinical studies indicate that gut microbial metabolism of
certain dietary nutrients can also influence development of
atherosclerosis (Bennett et al., 2013; Koeth et al., 2013; Tang
et al., 2013a; Wang et al., 2011; Tang and Hazen, 2014). Specif-
ically, gut microbial metabolism of phosphatidylcholine, the
major dietary source of choline, was first shown to produce a
proatherogenic metabolite, trimethylamine-N-oxide (TMAO),
via initial formation of trimethylamine (TMA), followed by host he-Cell Mpatic flavin monooxygenase-mediated conversion to TMAO
(Wang et al., 2011) (Figure S1, Gut Pathway 1, available online).
Subsequent studies identified an alternative trimethylamine
nutrient found predominantly in redmeat, L-carnitine, as another
dietary source for gut microbe-dependent formation of TMAO
and enhanced atherosclerosis (Koeth et al., 2013) (Figure S1,
Gut Pathway 2).
In recent human clinical studies, plasma carnitine levels in sub-
jects (n > 2,500) were independently associated with increased
future risk for myocardial infarction, stroke, or death, but only
among subjects with concomitantly high TMAO levels, consistent
with not carnitine, but the gut microbiota-dependent metabolite,
TMAO, serving as the culprit promoting the proatherosclerotic
phenotype (Koeth et al., 2013). TMAO formation from dietary L-
carnitine was shown to significantly associate with omnivorous
versus vegetarian or vegan eating habits and, together with mi-
crobiota composition, could discriminate chronic dietary patterns
in humans andmice, suggesting that gut microbial metabolism of
L-carnitine into TMAO may in part help explain the commonly
observed association between red meat consumption and car-
diovascular risks (Bernstein et al., 2010; Koeth et al., 2013; Micha
et al., 2010). Multiple mechanisms have been identified as
contributing to TMAO-dependent enhancement in atheroscle-
rosis, including inhibition of the reverse cholesterol transport
pathway, alterations in hepatic and intestinal cholesterol and
bile acid metabolism, and changes in macrophage phenotype
in the artery wall (Bennett et al., 2013; Koeth et al., 2013; Wang
et al., 2011). Importantly, in addition to the above-mentioned
relationship between carnitine levels and cardiac risks, human
clinical studies also demonstrate that plasma levels of choline
independently predict both prevalent and incident cardiovascular
disease (CVD) risks (Wang et al., 2011, 2014), and plasma TMAO
levels are similarly independently associated with risk of both
prevalent CVD (Wang et al., 2011) and prospective development
of major adverse cardiovascular events, including myocardial
infarction, stroke, and death (Koeth et al., 2013; Tang et al.,
2013a;Wang et al., 2014). Thus, a growing body of evidence sug-
gests amechanistic link between dietary trimethylamines such as
choline, phosphatidylcholine or L-carnitine, and development of
atherosclerosis via gut microbiome-dependent production of
TMAO (for review, see Tang et al., 2013b).
An obligatory role for gut microbes in the metabolism of dietary
L-carnitine into TMA and TMAO has been established in bothetabolism 20, 799–812, November 4, 2014 ª2014 Elsevier Inc. 799
Figure 1. gBB Is a Quantitatively Significant
Gut Microbe-Generated Metabolite of Die-
tary L-Carnitine
(A) Hypothesized scheme of carnitine metabolism
to TMA/TMAO through the intermediate produc-
tion of gBB by gut microbes.
(B) Stable isotope dilution LC-MS/MS analyses of
plasma gBB, L-carnitine, TMA and TMAO in
plasma of C57BL/6J Apoe/ female mice on the
indicated respective diets between the ages of
weaning and 19 weeks. Error bars represent ± SE,
and p values represent Wilcoxon rank-sum test.
(C) C57BL/6J Apoe/ female mice challenged
with d3-carnitine. Postchallenge measurement of
d3-metabolites was performed in serial venous
blood draws by stable isotope dilution LC-MS/MS.
(D) Female Swiss Webster germ-free mice (n = 4)
challenged with d3-L-carnitine before and after
conventionalization. Postchallenge measurement
of d3-L-carnitine and d3-gBB was performed in
serial venous blood draws by stable isotope dilu-
tion LC-MS/MS. Data are expressed as means ±
SE (see also Figure S1).
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however, the pathways and enzyme(s) bacteria use tometabolize
L-carnitine ultimately into TMA are poorly defined. Recently, Zhu
et al. (2014) reported the cloning of amicrobial enzyme capable of
using L-carnitine as substrate to form TMA, though its role in
TMAO generation in vivo is unknown. Prior studies exploring the
conversion of dietary L-carnitine into TMA/TMAO have not exam-
ined the possibility of sequential gut microbial reactions in the
metabolism of L-carnitine into TMA. Interestingly, an early study
in rats examining orally ingested radioactively labeled L-carnitine
reported that g-butyrobetaine (gBB), another trimethylamine, can
be produced (Rebouche et al., 1984) (Figure S1, Gut Pathway 3,
first reaction). g-butyrobetaine is used as a dietary supplement,
where it has also been called precarnitine (preCar) because of800 Cell Metabolism 20, 799–812, November 4, 2014 ª2014 Elsevier Inc.its known role as the immediate biosyn-
thetic precursor to carnitine during endog-
enous carnitine synthesis. L-carnitine is
not required in the diet. It is synthesized
by a multistep pathway that begins with
dietary lysine (Figure S1; Endogenous
Pathway), an abundant amino acid in
plant and animal proteins (Bremer, 1983;
Rebouche and Seim, 1998).
Little is known regarding the relation-
ship between gBB and the gut micro-
biome. Most studies consider the bio-
chemical pathway of gBB/ L-carnitine
as unidirectional, catalyzed by the endog-
enous enzyme gBB hydroxylase (Re-
bouche and Engel, 1980), with gBB being
a metabolite produced during L-carnitine
biosynthesis, not catabolism (Figure S1;
Endogenous Pathway). However, the
production of gBB from L-carnitine by a
gut microbial process has been sug-
gested (Rebouche and Chenard, 1991;Rebouche et al., 1984; Seim et al., 1985). Herein, we sought to
test the hypothesis that gBB may serve as a proatherogenic in-
termediate in TMA/TMAO formation from dietary L-carnitine (Fig-
ures 1A and S1, Gut Pathway 3). Such a finding would suggest
that additional potential bacterial pathways, and hence potential
pharmacological targets, are involved in the mechanism(s) link-
ing L-carnitine ingestion to enhanced atherosclerosis.
RESULTS
Gut Microbial Metabolism of L-Carnitine Produces gBB
as a Quantitatively Significant Product
To test whether gut microbial formation of gBB might represent
a unique intermediate in the proatherosclerotic effect of dietary
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A Microbial Atherogenic Intermediate of CarnitineL-carnitine and its conversion into TMA and TMAO (Koeth et al.,
2013), we first evaluated plasma levels of gBB versus TMA,
TMAO, or carnitine in C57BL/6J Apoe/ mice placed on either
a chemically defined diet (chow) or the same diet supplemented
with L-carnitine (with or without oral antibiotics cocktail to sup-
press gut microbes). Notably, plasma gBB levels in the L-carni-
tine-supplemented mice (without antibiotics) demonstrated an
almost 100-fold increase compared to chow-fed controls (Fig-
ure 1B). Further, suppression of gut microbes with an oral antibi-
otic cocktail virtually eliminated plasma levels of gBB, strongly
indicating that the majority of the analyte in L-carnitine-supple-
mented mice was derived from gut microbial metabolism of die-
tary L-carnitine and not via the endogenous biosynthesis
pathway. As was previously reported (Koeth et al., 2013), plasma
TMA and TMAO levels were also suppressed in mice placed
on the oral antibiotics, consistent with an obligatory role of gut
microbes in the formation of these metabolites. Remarkably,
plasma concentrations of gBB exceeded the concentration of
carnitine, TMA, or TMAO in the L-carnitine-supplemented mice
by approximately 2-fold, suggesting that production of gBB
was a major gut microbial metabolite produced from L-carnitine
(Figure 1B). Plasma clearance rates for trimethylamines were
also determined and observed to be within a factor of 2 of one
another, with elimination of gBB being faster than that of either
TMA or TMAO (Figure S2). Thus, in the carnitine-supplemented
mice, plasma gBB is not elevated relative to TMA or TMAO
due to a reduced clearance rate.
To confirm a direct precursor/ product relationship between
dietary L-carnitine and gBB formation via a gut microbe-depen-
dent process, conventional mice were provided L-d3(methyl)-
carnitine orally by gastric gavage, and then time-dependent
changes in plasma levels of the metabolites d3-gBB, d3-TMA,
and d3-TMAO were quantified (Figure 1C). Following ingestion,
d3-gBBwas observed, confirming a direct precursor/ product
relationship. Further, plasma levels of d3-gBB were significantly
higher than that of either d3-TMA or d3-TMAO, again indicating
that formation of gBB was a major metabolite formed from die-
tary L-carnitine. To directly establish a role for gut microbes in
gBB formation from dietary L-carnitine, synthetic L-d3(methyl)-
carnitine was again provided by gastric gavage, but this time
into germ-free mice. Serial plasma measurements following
oral L-d3(methyl)-carnitine showed no detectable d3-gBB
(Figure 1D). However, following housing in conventional cages
to permit gut colonization with microbes, repeat oral L-
d3(methyl)-carnitine challenge now readily showed d3-gBB in
plasma (Figure 1D). Collectively, these results indicate that die-
tary L-carnitine serves as a precursor for gut microbe-dependent
formation of gBB. Moreover, gBB is a quantitatively significant
L-carnitine metabolite formed by the gut microbiome.
gBB Produces TMA/TMAO in a Gut Microbe-Dependent
Manner
The demonstration of gBB production from dietary L-carnitine
raises the possibility that this trimethylamine might contribute
to TMA/TMAO formation by serving as an intermediate in gut
microbial metabolism of L-carnitine into TMAO. To test this hy-
pothesis, we first synthesized d9(trimethyl)-gBB (Experimental
Procedures) and then provided it by gastric gavage to conven-
tionally housed C57BL/6J mice. Quantification of predicted d9-Cell Misotopologues of various trimethylamines (gBB, TMA, TMAO,
carnitine, 3-dehydrocarnitine, choline, betaine, and trans-croto-
nobetaine) in plasma was performed by LC-MS/MS. No d9-
choline, d9-betaine, or d9-3-dehydrocarnitine was detected,
and only trace levels of d9-trans-crotonobetaine were observed
(over two orders of magnitude lower than d9-TMA or d9-TMAO;
data not shown). Time-dependent increases in both d9-TMA and
d9-TMAO are shown in Figure 2A (top row, left). Interestingly, d9-
carnitine was also produced (Figure 2A, second row, left). While
d9-carnitine formation from oral d9-gBB is consistent with gBB
conversion into L-carnitine via the endogenous synthesis
pathway, we could not rule out the possible contribution of gut
microbes to the d9-carnitine generation (at this juncture). After
marked reduction in gut microbe content with a period of oral
poorly absorbed broad-spectrum antibiotics, mice were again
challenged with d9-gBB by gastric gavage. Despite appearance
of the d9-gBB and d9-carnitine in plasma (again consistent with
the endogenous synthesis pathway), there was a complete
absence of any detectable d9-TMA or d9-TMAO in the circula-
tion, indicating a gut microbe dependence in TMA/TMAO forma-
tion from orally ingested gBB (Figure 2A, middle panels). After
withdrawal of the oral antibiotics and a period of housing the
mice in conventional cages to permit recolonization, there was
reacquisition of the capacity to produce d9-TMA and d9-
TMAO from oral d9-gBB, while production of d9-carnitine re-
mained similar to that observed in the two previous challenges
(Figure 2A, right panels). An obligatory role for gut microbes in
formation of d9-TMA and d9-TMAO from d9-gBBwas confirmed
by performing a similar oral challenge using germ-free (Swiss
Webster) mice (Figure 2B). As observed in the antibiotic-sup-
pressed C57BL/6J mice, no detectable d9-TMA or d9-TMAO
was formed following gastric gavage of mice with d9-gBB,
whereas d9-carnitine was produced, consistent with the endog-
enous (host) pathway. Following conventionalization, the prior
germ-free mice acquired the capacity to produce d9-TMA and
d9-TMAO from oral d9-gBB (Figure 2B).
gBB Formation Begins in a Location Anatomically
Proximal to TMA Formation and Is Quantitatively aMajor
Gut Microbial Metabolite of L-Carnitine
To further assess the relative synthetic capacity and location(s)
along the intestinal tract for gBB and TMA formation from both
L-carnitine and gBB, we coincubated molar equivalent amounts
of synthetic L-d3(methyl)-carnitine and d9(trimethyl)-gBB with
distinct anatomic segments of mouse intestines (including
luminal contents) and then examined production of the various
trimethylamines (carnitine, gBB, TMA). Use of the different isoto-
pically labeled precursors (d3-carnitine and d9-gBB) within gas-
tight reaction vials allowed us to simultaneously monitor direct
precursor/ product relationships individually for both carnitine
and gBB by quantifying the d3- and d9-isotopologue metabo-
lites formed from each precursor. Several results were noted
from this experiment. First, the main site of TMA production
from both carnitine and gBB was mainly in the bacterial rich
cecum, with formation of TMA from gBB occurring at a rate
approximately 1.5-fold higher than that from an equimolar
amount of L-carnitine (Figure 3A). Second, the small bowel
(jejunum and especially ileum) served as amajor initial site of pro-
duction of gBB from L-carnitine, anatomically proximal to thoseetabolism 20, 799–812, November 4, 2014 ª2014 Elsevier Inc. 801
Figure 2. Orally Ingested gBB Generates
TMA and TMAO via a Gut Microbe-Depen-
dent Pathway
(A) C57BL/6J female mice (n = 5) challenged with
d9-gBB gastric gavage (left panels: upper,
d9TMA/TMAO; lower, d9-L-carnitine and d9-gBB)
followed with serial blood venous blood draws and
quantification of deuterated plasma analytes by
stable isotope dilution LC-MS/MS. Repeat gastric
gavage with d9-gBB after 1 month of gut sup-
pression with a cocktail of broad-spectrum anti-
biotics as described in Experimental Procedures
(middle panels). A final d9-gBB gastric challenge
and sequential measurement of deuterated
plasma compounds (right panels) was performed
after a month long reconventionalization period.
(B) Female Swiss Webster germ-free mice (n = 5)
were challenged with d9-gBB before and after
conventionalization. Postchallenge measurement
of d9-TMA and d9-TMAO (upper panels) and d9-
L-carnitine and d9-gBB (lower panels) was per-
formed in serial venous blood draws by stable
isotope dilution LC-MS/MS. Data are expressed
as means ± SE (see also Figure S2).
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able 1,000-fold increase in d3-gBB production (relative to d3-
TMA) from d3-carnitine was noted. To further establish that
gBB production from carnitine is a dominant product of gut
microbial catabolism of carnitine, we also performed studies
to measure the potential production of alternative suspected or
hypothetical products, including trans-crotonobetaine, glycine
betaine (betaine), glycine, and 3-dehydrocarnitine (Kleber,
1997). We observed no detectable production of d3-isotopo-
logues of betaine, glycine, or 3-dehydrocarnitine either in plasma
(multiple time points between 0 and 24 hr) of C57BL/6J female
mice challenged (gastric gavage) with d3-carnitine or in the
ex vivo gut segment incubation experiments under either anaer-
obic or aerobic conditions (Figure S3 and data not shown). We
speculated that one potential reason these d3-trimethylamines
were not detected in plasma may be due to an accelerated
rate of elimination. However, the rates of plasma clearance of
synthetic deuterium-labeled forms of these trimethylamines
were not remarkably different compared to gBB (Figure S2).802 Cell Metabolism 20, 799–812, November 4, 2014 ª2014 Elsevier Inc.We did detect modest production of
trans-crotonobetaine in the ex vivo gut
segment experiments, as well as
following oral (gastric gavage) ingestion
(Figures S3 and S4). However, the pro-
duction of trans-crotonobetaine was
significantly (almost two orders of magni-
tude) less than the production of gBB or
TMA/TMAO from carnitine. In addition,
the plasma clearance rate of trans-
crotonobetaine was significantly slower,
not faster, than that observed with
gBB (Figure S2). Finally, in studies with
germ-free mice, we confirmed that the
trace levels of trans-crotonobetaine
formed were generated by gut microbessince virtually none was formed in the germ-free mice
(Figure S4B).
Collectively, our data thus suggested that sequential microbial
reactions (L-carnitine/ gBB, and then gBB/ TMA) were ama-
jor pathway for orally ingested L-carnitine conversion into TMA
and thus TMAO. However, given that our data opened the door
to considering the concept of sequential reactions, we thought
it prudent to perform additional studies to exclude amajor contri-
bution of alternative potential sequential pathways to either gBB
or TMA production from ingested L-carnitine. Focusing first on
generation of gBB from oral L-carnitine ingestion, we speculated
that other trimethylamines produced during gut microbial-
dependent catabolism of L-carnitine, including TMA or TMAO
themselves, might somehow serve as substrate to produce
gBB via gut microbes. However, we could not experimentally
demonstrate any d9-gBB formation from d9-TMA or d9-TMAO
either during ex vivo gut segment incubations (Figures S5A and
S5B) or following direct gastric gavage in mice (Figures S5C
and S5D). We also sought to test whether gut microbe-produced
Figure 3. Gut Microbes Convert L-Carnitine into gBB Anatomically Proximal to TMA, and the Microbial Enzyme yeaW/yeaX Shows TMA
Lyase Activity with Multiple Trimethylamine Nutrients
(A) C57BL/6J female mouse intestines (n = 7) were sectioned into two complementary pieces for incubation at 37C for 18 hr with equimolar amounts of d3-
L-carnitine (middle and right panels) or d9-gBB (left panel) under either aerobic (open bars) or anaerobic (closed bars) conditions, as indicated. Deuterated
trimethylamine analytes were quantified by stable isotope dilution LC-MS/MS, as described in the Experimental Procedures. d3-gBB production from d3-
L-carnitine is approximately 1,000-fold higher (right panel) than d3-TMA production (middle panel). Duo, duodenum; Jejen, jejenum; Cec, cecum.
(B) Cloning of yeaW/yeaX from E. coli DH10b into pET at NdeI and HindIII sites and transforming E. coli BL21.
(C) SDS-PAGE confirmation of the purified yeaW and yeaX from E. coliBL21 lysate transformedwith pET-yeaW and pET-yeaX, respectively. Both yeaWand yeaX
contain 83His tag.
(D) YeaW/X catalyzes production of TMA from multiple TMA-containing compounds. Data presented are mean ± SE for triplicate determinations from two
independent replicates of purified proteins (see also Figures S3–S7).
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A Microbial Atherogenic Intermediate of CarnitinegBB (e.g., proximally in small bowel) might be converted back to
carnitine, which could then be converted into TMA (i.e., gBB/
L-carnitine/ TMA). Indeed, the previous observation of the for-
mation of d9-carnitine from oral d9-gBB in conventional mice
(Figure 2) raises the possibility that in addition to the endogenous
synthesis pathway, gut microbes might have contributed to d9-
carnitine formation. Comparison of the amount of d9-carnitine
formed in conventional mice before or following antibiotic sup-
pression of gut microbes (and following conventionalization)
showed no difference in area under the curve (AUC) (i.e., the
AUC of d9-carnitine in preantibiotics or postantibiotics [p =
0.12] and AUC of d9-carnitine postantibiotics or conventionaliza-
tion [p = 0.69]; Figures 2A and S6). Similarly, comparison of the
AUC for d9-carnitine generation from oral d9-gBB in germ-free
mice before or after conventionalization (Figure 2B) revealed
no significant differences (p = 1.00). These results suggest that
no significant microbial production of d9-carnitine occurred
following d9-gBB ingestion.
In separate experiments, we looked at the effect of mildronate,
a reported gBB hydroxylase inhibitor, on d9-carnitine generation
from oral d9-gBB in the hopes that this inhibitor (a carnitine hy-
drazine analog) might serve as a tool to specifically inhibit the
endogenous carnitine biosynthesis pathway. However, control
studies showed that it was rather nonspecific, inhibiting several
microbial reactions (e.g., gut microbial production of TMA from
gBB, data not shown). Tomore directly test for a potential micro-
bial contribution to the observed d9-carnitine in plasma following
d9-gBB ingestion, we quantified the production of d9-carnitine
(and d9-betaine) from d9-gBB in freshly harvested gut segments
incubated ex vivo under either aerobic or anaerobic conditions.
No detectable d9-carnitine (or d9-betaine) production was
observed (Figure S7), despite clear d9-TMA production (Fig-
ure 3). In a last set of studies, we tested whether the circulating
d9-carnitine observed (via endogenous pathway) following d9-
gBB ingestion might reenter the intestinal lumen (via diffusion
or enterohepatic cycling) to ultimately produce d9-TMA and
d9-TMAO. Two groups of mice were provided an equivalent
amount of d9-carnitine via either oral (gastric gavage) or paren-
teral (intraperitoneal injection) route, and the time course of
changes in plasma d9-carnitine and d9-TMAO was monitored
(Figure S7). While the plasma levels of d9-carnitine achieved in
the two groups of mice were on the whole similar (i.e., within
approximately a factor of two), the concentrations of plasma
d9-TMAO observed were dramatically reduced (>100-fold less)
in the mice that received parenteral d9-carnitine. Thus, carnitine
synthesized via the endogenous pathway from gBB enters the
circulation and essentially bypasses the gut lumen (and mi-
crobes) and does not significantly contribute to observed TMA/
TMAO generation.
Identification of a Microbial Enzyme Complex,
yeaW/yeaX, that Directly Produces TMA from gBB
It has long been known that some cultured bacterial isolates can
use L-carnitine as a major carbon source and form TMA (Seim
et al., 1982a, 1982b; Unemoto et al., 1966). Moreover, very
recently, using bioinformatics approaches with Acinetobacter
baumannii as the model, a two-component Rieske-type oxy-
genase/reductase capable of using L-carnitine in culture and
producing TMA was reported (Zhu et al., 2014). We too had804 Cell Metabolism 20, 799–812, November 4, 2014 ª2014 Elsevierused a similar bioinformatics search strategy to identify microbi-
al carnitine TMA lyases. We searched for microbial enzymes of
unknown function that were clustered with those known to syn-
thesize or use either malate or succinate (potential products
formed following carntine utilization) and a presumed betaine-
carnitine-choline transporter. One potential candidate was the
gene pair previously called yeaW/X in E. coli DH10B (yeaW [di-
oxygenase], GeneID 6060925; yeaX [oxidoreductase], GeneID
6060982). Using a modified pET20 plasmid, we transformed
E. coli BL21pLysS with each allele and subsequently individually
purified recombinant yeaW and yeaX from bacterial lysates (Fig-
ures 3B and 3C). When the purified proteins are combined, the
yeaW/X complex demonstrated carnitine TMA lyase activity
(monitored by d9-TMA production from d9-carnitine). Interest-
ingly, further characterization of the recombinant microbial
yeaW/X complex revealed substrate promiscuity, catalyzing
production of d9-TMA from multiple synthetic d9-trimethyl-
amine precursors (gBB, L-carnitine, choline, and betaine;
Figure 3D).
Gut Microbial Metabolism of Dietary gBB Accelerates
Atherosclerosis
We next sought to test whether gBB could contribute to the
enhanced development of atherosclerosis previously observed
in mice placed on a diet supplemented with L-carnitine (Koeth
et al., 2013). C57BL/6J Apoe/ littermates at time of weaning
were placed in separate cages on a chemically defined diet
equivalent to normal chow or the same diet supplemented with
gBB (1.3%, gm/gm). In parallel, in half the mice, gut microbes
were suppressed by incorporating a cocktail of poorly absorbed
antibiotics within the drinking water (Experimental Procedures).
At 19 weeks of age, mice were sacrificed and aortic root athero-
sclerotic plaque was quantified (Figures 4A and 4B). A significant
50% increase in total area of plaque was noted within the gBB
diet-supplemented mice compared to their littermate controls
on chow diet (Figures 4A and 4B). Importantly, no increase in to-
tal plaque area was observed in mice on the gBB-supplemented
diet in which gut microbes were suppressed by the antibiotics
cocktail (+ABS). Analyses of plasma levels of carnitine, gBB,
TMA, and TMAO showed that neither carnitine nor gBB were
likely the direct proatherogenic species since they remained
high in the gBB-fed mice on antibiotics (Figure 4C). In fact,
gBB-supplemented mice receiving antibiotics had the highest
plasma gBB concentrations observed yet showed no increase
in atherosclerosis plaque (Figures 4A and 4B).
In parallel studies, we explored whether changes in known
metabolic parameters that impact atherosclerosis might help
explain the changes in aortic root plaque area observed between
the groups of mice. Analyses of plasma cholesterol levels
showed no differences among the mouse groups. A modest
but statistically significant increase in plasma and liver triglycer-
ide concentrations was observed within the gBB-supplemented
mice (Table S1). A similar modest significant increase in plasma
triglyceride concentrations, however, was also noted within anti-
biotic-treated mice in the gBB-supplemented dietary arm or
controls (chow +ABS; Table S1). Further analyses of plasma
showed no other proatherosclerotic alterations, with compara-
ble HDL cholesterol and glucose levels observed among the
different groups of mice.Inc.
Figure 4. Dietary gBB Promotes Atherosclerosis in a Gut Microbe-Dependent Manner
(A) Oil red O-stained and hematoxylin-counterstained representative aortic root slides of 19-week-old C57BL/6J Apoe/ female mice on the indicated diets in
the presence or absence of gut microbe suppression (with or without antibiotics [ABS]), as described in the Experimental Procedures.
(B) Quantification of mouse aortic root plaque lesion area of 19-week-old C57BL/6J Apoe/ female mice. Mice were started on the indicated diets at the time of
weaning (4 weeks of age). Lesion area was quantified as described in the Experimental Procedures.
(C) Terminal plasma concentrations of gBB, L-carnitine, TMA, and TMAOwere determined using stable isotope dilution LC-MS/MS analysis. Data are expressed
as means ± SE (see also Table S1).
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Inducible Trait
Wepreviously reported that gutmicrobe-dependent formation of
TMA and TMAO from dietary L-carnitine is enhanced following
chronic exposure, presumably due to compositional changes
within the intestinal microbial community (Koeth et al., 2013).
We therefore tested if gut microbial production of gBB from die-
tary L-carnitine was similarly inducible. L-carnitine challenges
(gastric gavage with synthetic d3-L-carnitine) were performed
in 10-week-old C57BL/6J Apoe/ mice that had been main-
tained since weaning on either a chemically defined diet compa-
rable to chow or an otherwise identical diet supplemented with
L-carnitine (1.3 g%). Following oral d3-carnitine ingestion, pro-
duction of d3-gBB was several-fold higher in mice that had
been maintained on the L-carnitine-supplemented diet or chow
(Figure 5A). As previously described (Koeth et al., 2013), produc-
tion of both d3-TMA and d3-TMAO was also significantly
induced in the L-carnitine-supplemented mice, and plasma con-
centrations of d3-carnitine were significantly lower (consistentCell Mwith a large portion of dietary L-carnitine being catabolized at
greater efficiency by gut microbes following the chronic dietary
exposure) (Figure 5A). When the mice on L-carnitine or chow
(control) diet were instead challenged with synthetic d9-gBB,
no differences in d9-TMAO or d9-TMA production were noted.
Moreover, postprandial (gastric gavage with d9-gBB) plasma
levels of d9-gBB between L-carnitine-supplemented or chow
mice were equivalent. These results indicate that there is a
remarkable functional specificity induced following chronic L-
carnitine exposure for gut microbe-dependent metabolism of
the proximal dietary nutrient provided in abundance, L-carnitine,
but not the more downstream metabolite, gBB (Figure 5B).
Further, a significant increase in plasma d9-carnitine was noted
in chow (control) mice compared to the L-carnitine-supple-
mented mice. These latter data are consistent with oral d9-
gBB being absorbed and converted into d9-carnitine in normal
chow-fed mice and suppression of the endogenous L-carnitine
biosynthesis pathway in mice supplemented with L-carnitine
(Rebouche, 1983) (Figure 5B).etabolism 20, 799–812, November 4, 2014 ª2014 Elsevier Inc. 805
Figure 5. Mice Chronically Exposed to Die-
tary L-Carnitine Demonstrate Selective
Enhancement in Gut Microbial Functional
Capacity to Produce gBB and TMA/TMAO
from L-Carnitine, but Not from gBB
(A) D3-L-carnitine challenge of mice on an L-
carnitine-supplemented diet (1.3%) from weaning
until 10 weeks of age or age-matched normal
chow controls. Plasma concentrations of d3-gBB,
d3-L-carnitine, d3-TMA, and d3-TMAO were
measured in sequential venous blood draws at
the indicated times post d3-L-carnitine challenge
using stable isotope dilution LC-MS/MS. Data
points represent mean ± SE of four replicates per
group.
(B) The same C57Bl/6J Apoe/ mice on L-
carnitine and normal chow were challenged with
d9-gBB oral gavage followed by venous blood
draws at the indicated times over 12 hr. D9-gBB,
d9-L-carnitine, d9-TMA, and d9-TMAO levels
were analyzed using stable isotope dilution LC-
MS/MS. Error bars represent ± SE, and p values
represent Wilcoxon rank-sum test of the mean of
the area under the curve for each replicate
mouse.
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of gBB versus TMA or TMAO from Dietary L-Carnitine
We next sought to test whether the enhancement of gBB or
TMA/TMAO production observed from L-carnitine in the
chronic L-carnitine-supplemented mice indicated enrichment
of distinct taxa better suited for either gBB or TMA/TMAO pro-
duction. Microbial compositional analyses of intestinal contents
recovered from L-carnitine or chow-supplemented mice were
performed by sequencing 16S rRNA gene amplicons from
cecum of mice. We initially characterized the gut microbiota
of the cecum, a major site of carnitine conversion into both806 Cell Metabolism 20, 799–812, November 4, 2014 ª2014 Elsevier Inc.gBB and TMA. In parallel, stable isotope
dilution LC-MS/MS analyses were per-
formed to quantify plasma levels of gut
microbe-dependent metabolites of L-
carnitine (gBB, TMA, and TMAO) within
mice. Global analyses revealed that mul-
tiple microbial genera showed increased
proportions coincident with increased
plasma levels of either gBB or TMAO af-
ter testing for multiple comparisons (Fig-
ures 6A and 6B). In separate analyses,
we examined 16S rRNA gene amplicons
recovered from not only cecum, but also
sections of small bowel shown to
possess gBB production activity (ilium
and jejunum) from mice initially co-
housed until time of weaning, where-
upon they were separated and individu-
ally housed and maintained chronically
on the indicated diets (gBB or carnitine)
(Table S2). Interestingly, multiple similar
taxa in the cecum were observed to
have proportions that were significantlyassociated with levels of gBB (e.g., genera of Parasutterella,
Prevotella, and Bacteroides), but they were distinct from taxa
associated with TMAO levels. Further, the only microbial taxa
in the small bowel (jejunum) that was significantly (FDR
adjusted) associated with gBB levels was staphylococcus,
which in cecum was not significantly associated with gBB
levels (Table S2). Also notable, the genus Akkermansia mucini-
philia was significantly associated with TMAO production in
gBB-supplemented mice in both the cecum and ilium but
was not significantly associated (all gut segment examined)
with TMAO levels in carnitine-supplemented mice.
Figure 6. Chronic Dietary Exposure to L-Carnitine or gBB Influences Global Function of the Gut Microbiome
(A and B) Plasma gBB (A) or TMAO (B) concentrationswere determined by stable isotope dilution LC-MS/MS (plotted on x axes), and the proportion of operational
taxonomic units (OTUs, plotted on y axes) were determined as described in the Experimental Procedures. The p value (FDR correction) shown is for comparisons
between L-carnitine and normal chow dietary groups.
(C) Mice on a 1.3% gBB-supplemented diet fromweaning until 10 weeks of age (n = 4) and age-matchedmice on a normal chow diet (n = 5) were challenged with
d9-gBB oral gavage. Plasma concentrations of d9-gBB, d9-L-carnitine, d9-TMA, and d9-TMAO recovered by sequential venous blood draws were measured
using stable isotope dilution LC-MS/MS. p values represent Wilcoxon rank-sum test of the mean of the area under the curve for each replicate mouse.
(D) Mice on a 1.3% gBB-supplemented diet at 10 weeks of age (n = 4) and age-matchedmice on a normal chow diet (n = 5) were challenged with d3-carnitine oral
gavage. Plasma concentrations of d3-gBB, d3-L-carnitine, d3-TMA, and d3-TMAO recovered by sequential venous blood draws were measured using stable
isotope dilution LC-MS/MS. p values represent Wilcoxon rank-sum test of the mean of the area under the curve for each replicate mouse (see also Table S2). All
error bars represent ± SE.
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Also an Inducible Trait with Distinct Microbial Taxa
Associated with TMA and TMAO
The production of gBB from L-carnitine in the gut suggested that
gBB may also be involved in shaping the composition and func-Cell Mtion of gut microbial communities. At the time we performed the
studies examining mice on L-carnitine or chow diets (described
above), we examined (in parallel) cohoused C57BL/6J Apoe/
littermates that were separated at time of weaning and main-
tained on either a chemically defined diet comparable to chowetabolism 20, 799–812, November 4, 2014 ª2014 Elsevier Inc. 807
Figure 7. Overall Scheme Showing Gut
Microbe-Dependent Pathways for Conver-
sion of Dietary L-Carnitine into the Proa-
therosclerotic Metabolite TMAO
gBB is endogenously produced as part of the L-
carnitine biosynthetic pathway from lysine but can
also be produced by the metabolism of L-carnitine
by commensal gut microbes. L-carnitine and gBB
both serve as sources of TMA production via gut
microbes.
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for a similar period of time (weaning until 10 weeks of age) and
then performed both gut microbial compositional analyses and
quantification of plasma TMA and TMAO levels. Plasma TMAO
levels were significantly associated with the relative abundances
of a distinct microbial genera, Akkermansia muciniphilia from the
family Verrucomicrobia, within the cecum recovered from the
gBB-supplemented mice (Figures 6B). Further analyses were
performed on mice placed on either L-carnitine or gBB diets
(1.3 g% each), as described above, 16S rRNA gene amplicons
were analyzed fromdifferent segments of the intestines (jejunum,
ilium, and cecum), and (in parallel) plasma TMA, TMAO, and gBB
levels were determined. Plasma TMAO levels were significantly
associated with the relative abundance of Akkermansia mucini-
philiawithin the jejunumand cecum recovered from gBB-supple-
mented mice (Table S2). Interestingly, TMA and TMAO produc-
tion in the gBB-supplemented mice showed no association
with bacteria from the Bacteroides or Proteobacteria phyla,
taxa that coassociated with plasma gBB levels in L-carnitine-
fed mice (Table S2). Additionally, further global analyses of
plasma concentrations of TMA and TMAO from mice on either
carnitine-supplemented or gBB-supplemented diets demon-
strate virtually no overlap among proportions of gut microbiota
genera that associated with plasma TMA/TMAO levels, suggest-
ing that distinct genera may contribute to the metabolism of gBB
into TMA/TMAO or gut microbial metabolism of dietary L-carni-
tine into TMA/TMAO (Table S2).
To further explore potential functional metabolic differences
between the microbes that contribute to dietary gBB or dietary
L-carnitine metabolism into TMA/TMAO, we took initially co-
housed C57BL/6J Apoe/ mice and at the time of weaning
placed them into individual cages with either chemically defined
(chow) or gBB-supplemented (1.3%) diet. After chronic expo-
sure to the diets (10 weeks old), we challenged the mice with
gastric gavage of equimolar amounts of d9-gBB and d3-carni-
tine (Figure 6C). Production of plasma d9-TMA and d9-TMAO
from the d9-gBB was markedly higher in the mice that had
been on the gBB-supplemented diet, consistent with functional
induction of microbes optimized to use gBB as a fuel source
following long-term dietary exposure (Figure 6B). Correspond-
ingly, the postprandial plasma levels of d9-gBB observed were808 Cell Metabolism 20, 799–812, November 4, 2014 ª2014 Elsevier Inc.lower in the gBB-supplemented mice,
consistent with the previous dietary
exposure inducing enhanced catabolic
capacity of specific taxa better suited to
utilize gBB as a fuel source (and TMA/
TMAO formation) (Figure 6B). Notably,the gBB-supplemented mice failed to show enhanced d3-
TMAO production following gavage with d3-carnitine (p = 0.55;
Figure 6D) but did show modest increases in the production
of d3-TMA and d3-gBB (Figure 6D). The small increases in
d3-TMA production paralleled the kinetics of production of d3-
gBB and may thus be the result of microbial metabolism of d3-
gBB formed within the gut (luminal) (i.e., oral d3-carnitine /
gut (microbial) d3-gBB/ d3-TMA/ d3-TMAO). Thus, chronic
exposure to diets equivalent in chemical composition except for
the addition of either L-carnitine or gBB, despite their remarkable
similarity in structure, resulted in the development of functionally
distinct microbial communities optimized for the catabolism of
L-carnitine or gBB.
DISCUSSION
The present studies unambiguously show that gut microbial
catabolism of L-carnitine into TMA/TMAO in mice can occur
via at least two distinct routes involving functionally distinct
genera of microbiota (Figure 7). The first pathway represents
the direct scission of the C-N bond in L-carnitine liberating
TMA within the cecum and proximal large bowel, which is then
converted into TMAO by host FMO3, as previously described
(Koeth et al., 2013). The second pathway involves the catabolism
of L-carnitine through two sequential microbial reactions, first
into the intermediate gBB and then into TMA, which is then
converted into TMAO by host hepatic FMO3 (Figure 7). Both
functionally and compositionally distinct genera of microbes
associate with this latter pathway, which appears to quantita-
tively account for a majority of L-carnitine catabolism in the
mouse gut microbiome. Further, the anatomical distribution of
gut microbial production of gBB from L-carnitine is distinct
from that observed for direct TMAproduction. In the small bowel,
where the bacterial load is considerably reduced compared to
cecum and colon, L-carnitine catabolism to gBB begins. More-
over, biochemical assays along the intestinal tract indicate that
gBB formation in this proximal site occurs at a rate kinetically
favored 1,000-fold compared to direct cleavage of L-carnitine
into TMA (Figure 7). There have been previous studies demon-
strating that gut microbes can convert carnitine into gBB (Re-
bouche et al., 1984; Seim et al., 1985). Additionally, there is a
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isolate Acinetobacter calcoaceticu (Seim et al., 1977). However,
no studies have linked either gBB to TMA generation in vivo or
the sequential catabolism of L-carnitine into TMA and TMAO
via the intermediate gBB. Further, the present studies show a
proatherosclerotic effect of orally ingested gBB in the murine
model (Figure 7).
Through a variety of studies, we sought to rule out a quantita-
tively significant contribution of other alternative sequential
microbe-catalyzed pathways within the intestinal lumen besides
the proposed L-carnitine / gBB / TMA/TMAO pathway
(Figure 7). We first investigated whether or not L-carnitine /
TMA/ gBB or TMA (or TMAO)/ gBB was plausible. Neither
oral ingestion nor gut segment incubations under a variety of con-
ditions with d9-TMA or d9-TMAO resulted in detectable genera-
tion of d9-gBB or d9-carnitine, arguing that these more terminal
trimethylamine catabolites do not significantly participate as an
intermediate in the formation of gBB. Similarly, no d9-carnitine
could be detected following gut segment incubations with d9-
gBB, d9-TMA, or d9-TMAO. These latter studies strongly argue
against microbe-generated gBB formed in the proximal small
bowel being subsequently converted by microbes into carnitine
further down the intestinal tract (i.e., gBB / (via microbes)
L-carnitine/TMA in thececumandmoredistal colonasapoten-
tial pathway does not occur). Orally ingested d9-gBB does result
in detection of d9-carnitine within plasma in both germ-free and
conventionalmice, consistentwith the endogenous carnitine syn-
thesis pathway (Figure 7). However, no significant conversion of
parenterally administered d3-carnitine into d3-TMA or d3-TMAO
wasobserved in comparison to an oral route, despite comparable
plasma levels of carnitine achieved. Thus, once in the circulation
(a separate compartment from gut microbes), carnitine does not
significantly contribute quantitatively to TMA and TMAO forma-
tion. Additionally, quantification of other trimethylamines like
betaine, 3-dehydrocarnitine, choline, and the related metabolite
glycine similarly failed to indicate any significant metabolic pro-
duction by thegutmicrobial community following isotope-labeled
carnitine ingestion. Only a minimal level (two orders of magnitude
less) of d3-trans-crotonobetainewasdetected following ingestion
of d3-carnitine, and our studies with gut segments show similarly
modest trans-crotonobetaine production. Thus, while some
contribution of trans-crotonobetaine in TMA production may
occur (e.g., L-carnitine/ trans-crotonobetaine/ TMA, L-carni-
tine/ trans-crotonobetaine/ gBB/ TMA, or L-carnitine/
gBB/ trans-crotonobetaine/TMA), our data collectively argue
that the overall contribution of trans-crotonobetaine to TMA and
TMAO formation in vivo will be modest. Also notable is our identi-
fication and cloning of yeaW/X, a promiscuous microbial TMA
lyase complex capable of catalyzing the C-N bond cleavage of
multiple trimethylamine substrates including gBB, thus affirming
that gut microbial enzyme machinery exists for generating TMA
directly from gBB. Finally, by synthesizing heavy isotope-labeled
standards of the various trimethylamines, we were able to
examine their rates of plasma clearance. These studies showed
that the high plasma levels of gBB were not the result of slower
elimination. Our studies thus collectively indicate that the sequen-
tial conversion of L-carnitine/ gBB/ TMA serves as a major
gut microbial pathway for conversion of L-carnitine into TMA in
the rodent model (Figure 7).Cell MAnother interesting finding is that the production of gBB from
L-carnitine in the gut is much more proximally distributed than
TMA generation, beginning in the mid and distal small bowel
(latter part of jejunum and ileum). This contrasts with the site of
gut microbial production of TMA from either L-carnitine or
gBB, which is localized to the cecum and proximal large bowel.
L-carnitine ismostly absorbed through active transport in the up-
per gastrointestinal tract, and only when the active transport sys-
tem is saturated will appreciable levels of L-carnitine reach the
more distal segments of the gastrointestinal tract to be catabo-
lized by the gut micobiota (Rebouche and Seim, 1998). The
more proximal anatomical location of gBB formation thus further
argues for its physiological relevance. We acknowledge, howev-
er, that the ex vivo gut segment incubations have the inherent
limitation of not being subject to neuroendocrine inputs or the
dynamic metabolism of the intact GI tract within a host. As
such, conclusions from these experiments should be considered
in this context. Despite these limitations, it is noteworthy that the
distinct cecal microbial taxa identified whose proportions are
associated with TMA or TMAO production from dietary L-carni-
tine in the past (Koeth et al., 2013) (e.g., Prevotella, Mucispiril-
lium, Prevotellaceae-Unclassified, Anaeroplasma) or present
studies (Lachnospiraceae or other Ruminococcaceae), or from
dietary gBB in the present studies (e.g., Bacteroides, Prevotella,
Parasutterella, and several taxa from the phyla Proteobacteria),
are known to be predominantly populated with anaerobic spe-
cies. The discovery that gut microbial metabolism of L-carnitine
involves a second quantitatively significant sequential pathway
for TMA formation from distinct microbial taxa suggests that
numerous targets are at hand if one wishes to pharmacologically
manipulate the catabolism of carnitine into TMA/TMAO for po-
tential treatment or prevention of CVD, such as through shifting
of gut bacterial composition (probiotic, prebiotic) or inhibition
of bacterial enzymatic activities.
Early studies demonstrated that mammals completely lack the
capacity to catabolize L-carnitine (Bremer, 1983; Kleber, 1997;
Rebouche and Chenard, 1991). The importance of gBB in
mammalian physiology has thus traditionally centered on its
role in L-carnitine endogenous biosynthesis, where gBB serves
as the proximal biosynthetic intermediate in endogenous
L-carnitine production that begins with dietary lysine and also
utilizes methionine (Figure 7) (Bremer, 1983; Rebouche, 1983;
Rebouche and Chenard, 1991). Our results reveal the quantita-
tive importance of gBB as an unrecognized intermediate in the
multistep catabolism of L-carnitine by the gut microbiome into
TMA and TMAO formation in mice. The results herein also allude
to the complexity of the ‘‘meta-metabolome.’’ In the present
case, sequential symbiotic microbial community-host inter-
actions participate in an overall metaorganismal pathway that
impacts the development of a complex phenotypic trait, athero-
sclerosis. The complexity of the global metabolome that reflects
both host and symbiont inputs is even more evident when one
considers that host genetic factors influence gut microbial com-
munities, while diet shapes gut inhabitant composition (Wu et al.,
2011). Thus, the interaction between host genetic factors, die-
tary and other environmental exposures, and microbial factors
collectively contributes to the overall metabolic network or
meta-metabolome that impacts atherosclerosis expression in
the present example.etabolism 20, 799–812, November 4, 2014 ª2014 Elsevier Inc. 809
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involving dietary supplementation with choline (Wang et al.,
2011) and L-carnitine (Koeth et al., 2013), supplementation of
gBB also increased atherosclerotic plaque area in a gut
microbe-dependent manner. From a mechanistic standpoint,
the present data clarify that gut microbial metabolism of gBB to
TMA/TMAO, and not gBB itself directly, is associated with
enhanced atherosclerosis. This conclusion is supported by the
observation that mice supplemented with gBB and concomi-
tantly treated with oral antibiotics to suppress gut microbes
(and TMA/TMAO production) did not have an increase in aortic
root atherosclerotic plaque area, despite having the highest
plasma concentrations of gBB. Rather, mice with the highest
plasma concentrations of TMAO had the most plaque at the
aortic root, whereas those with suppressed gut microbes and
lacking TMA/TMAOshowed no increase in atherosclerosis.While
multiple human studies with distinct clinical populations have
now confirmed a strong association between plasma TMAO
levels and cardiovascular disease risks (Koeth et al., 2013;
Tang et al., 2013a, 2013a; Wang et al., 2011, 2014), a causal
role between TMAO and atherosclerosis and its adverse events
in humans remains to be proven. Despite these limitations, taken
together with prior studies demonstrating direct proatheroscler-
otic effects of dietary TMAO in the murine model (Koeth et al.,
2013; Wang et al., 2011), the present studies add to the growing
data indicating that enhanced microbial production of TMA, and
subsequently TMAO, fosters a proatherogenic phenotype.
One of the more notable findings of the present study is the
extreme functional plasticity of the gut microbial community in
response to relatively small dietary changes. Previous studies
from our laboratory (Koeth et al., 2013) and others (Muegge
et al., 2011; Wu et al., 2011; Zimmer et al., 2012) have demon-
strated that preceding dietary habits can greatly influence the
gut microbial composition. In general, these studies have been
observational, exploring the influence of long-standing eating
habits with large changes in complex dietary nutrients (e.g.,
meat eaters [omnivores] or high-fiber vegetarian or vegan diets)
(Cotillard et al., 2013; David et al., 2014; Faith et al., 2013; Koeth
et al., 2013; Muegge et al., 2011; Wang et al., 2011; Wu et al.,
2011; Zimmer et al., 2012). In the present studies, however, it
is noteworthy that the dietary differences between animal groups
were quite modest. The only structural difference between gBB
and L-carnitine is the presence of a hydroxyl group at carbon 3 in
carnitine (Figure 7). Yet despite the close structural similarity,
distinct gut (cecal, jejunal, and ileal) microbial compositions
with discernibly distinct biochemical functionality were observed
in mice chronically fed diets identical in composition except
for modest supplementation with equivalent amounts of either
L-carnitine or gBB. Remarkably, chronic L-carnitine-supple-
mented mice demonstrated marked induced synthetic capacity
to produce TMAO from L-carnitine, but not gBB, whereas mice
chronically supplemented with gBB demonstrated enhanced
TMAO formation from oral gBB, but not L-carnitine. Furthermore,
gut microbial taxa that are associated with the metabolism of L-
carnitine to gBB, the first step in the pathway, were also mostly
different from the taxa associated with L-carnitine metabolism
into TMA /TMAO (Table S2). It remains unclear whether diet-
induced differences in microbial composition or other mecha-
nisms such as transcriptional or posttranscriptional regulation810 Cell Metabolism 20, 799–812, November 4, 2014 ª2014 Elsevierof microbial enzymes (or more likely a combination) are respon-
sible for the functional differences observed. Indeed, there are
data to show that bacterial isolates grown on L-carnitine can
induce enzymes involved in carnitine catabolism (Aurich, 1966;
Seim et al., 1982b). Regardless, even the subtle dietary change
employed in the present studies between L-carnitine or gBB
supplementation was sufficient to substantially alter the gut mi-
crobial community biochemical output and function.
In summary, the present studies reveal that gBB serves as a
gut microbial intermediate in the metabolism of L-carnitine to
TMA/TMAO and provides an important advance in further under-
standing the connection between gut microbe-dependent meta-
bolism of L-carnitine and atherosclerosis. Over-the-counter
supplementation with gBB (PreCar) is marketed as a direct to
consumer product. Indeed, over-the-counter nutritional supple-
ments in general is a rapidly growing commercial enterprise, yet
it falls outside of the mandate of the Food and Drug Adminis-
tration and only needs to demonstrate minimal safety data.
Although there are no current studies directly linking gBB to hu-
man atherosclerosis, the present studies suggest that additional
investigation into gBB and atherosclerosis pathogenesis is war-
ranted, as are long-term safety studies with supplemental gBB,
as well as choline and carnitine, particularly within otherwise
healthy individuals where no clinical benefit with supplementa-
tion is established.
EXPERIMENTAL PROCEDURES
Materials and General Procedures
All animal studies were performed under approval of the Animal Research
Committee of the Cleveland Clinic. Mouse plasma total cholesterol and triglyc-
erides were measured using the Abbott ARCHITECT platform model ci8200
(Abbott Diagnostics). HDL cholesterol concentration, liver triglyceride, and
cholesterol contents were quantified as previously described (Wang et al.,
2011). Gut microbial suppression studies were performed by dissolving
antibiotics in drinking water (Wang et al., 2011). D3(methyl)-betaine and d9(tri-
methyl)-betaine were purchased from C/D/N Isotopes, and d9-TMA and
d9-TMAO were purchased from Cambridge Isotope Laboratories.
Mouse Challenge and Atherosclerosis Studies
An oral gBB or L-carnitine challenge in mice consisted of a gastric gavage of
150 ml of 150 mM d9-gBB or d3-L-carnitine dissolved in water, respectively,
and as further described in the Supplemental Experimental Procedures.
C57BL/6J Apoe/ female mice used in atherosclerosis studies were placed
on a standard chow control diet (Teklad 2018) or gBB-supplemented diet
(mouse drinking water with 1.3% gBB; BOC Sciences) in the presence or
absence of antibiotics at the time of weaning, as further described in the Sup-
plemental Experimental Procedures.
Mouse Microbiota and Statistical Analyses
Microbial community composition was assessed by pyrosequencing 16S
rRNA genes derived from themice cecum, jejunum, or ilium ofmice on the indi-
cated diets as described in detail within the Supplemental Experimental Pro-
cedures. Briefly, DNA was isolated using the MoBio PowerSoil DNA isolation
kit according to the manufacturer’s instructions and sequenced using 454
GS FLX titanium chemistry at the GenoSeq Facility at the University of Califor-
nia, Los Angeles. Sequences that passed quality control were analyzed and
assigned to operational taxonomic units (OTUs) using UCLUST, and the taxo-
nomic composition was assigned using Ribosomal Database Project (RDP)
Classifier 2.0.1 (Wang et al., 2007). All data were analyzed using R software
version 2.15 (JMP, SAS Institute). False discovery rates (FDRs) of the multiple
comparisons were estimated for each taxon based on the p values resulting
from Spearman correlation estimates. The Wilcoxon rank-sum test was used
for two-group comparison.Inc.
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Quantification of Trimethylamines
Detailed descriptions of syntheses, isolation, and characterization of all com-
pounds are described in the Supplemental Experimental Procedures. Briefly,
d9-gBB was prepared as the chloride salt (3-carboxypropyl)trimethyl(d9)
ammonium chloride; d9-gBB) from g-aminobutyric acid in methanol with po-
tassium hydrogen carbonate and d3-methyl iodide (all from Sigma-Aldrich)
(Morano et al., 2008). D9-(trimethyl)-trans-crotonobetaine was prepared by
acid treatment of L-carnitine using a modification of a previously described
method (Heinz and Hermann, 1996). D3(methyl)-L-carnitine was synthesized
by methylating L-norcarnitine with CD3I (Koeth et al., 2013). Racemic d9-(tri-
methyl)carnitine was prepared in an analogous manner to d3-L-carnitine, but
starting with 4-amino-3-hydroxybutyric acid (Chem Impex International). The
purity (>98%) and identity of all compounds were confirmed by NMR, mass
spectrometry, and thin-layer chromatography. Stable isotope dilution LC-
MS/MS (Koeth et al., 2013; Wang et al., 2011, 2014) was used to quantify
trimethylamine compounds from mouse plasma (and diets) in positive ion
MRM mode. Precursor/ product ion transitions specific for each trimethyl-
amine isotopologue are further described in the Supplemental Experimental
Procedures.
Plasma Clearance Studies
C57BL/6J female mice were injected intravenously (i.v.) with an equimolar
isotonic neutral pH cocktail of synthetic d9-gBB, d3-carnitine, d9-TMAO,
d9-TMA, d9-trans-crotonobetaine, and d9-betaine. Multiple sequential
venous blood draws were performed over a 1 hr period, and the concentration
of the respective isotopologues of the various labeled trimethylamines was
determined by LC-MS/MS. Initial plasma clearance rates were determined us-
ing the equation Ct = Co3 ek(t), where Ct is the final concentration (defined at
60 min), Co is the initial (peak) concentration, k is the calculated rate constant,
and t is time (1 hr).
Ex Vivo Mouse Gut Segment Incubations
C57BL/6J female mouse (n = 7) intestines were harvested, sectioned into the
indicated anatomic parts, and then each piece was longitudinally cut into two
halves and placed into gas-tight reaction vials containing 50mMHEPES buffer
(pH 7.4) and 150 mM each of d9-gBB and/or d3-L-carnitine, respectively, de-
pending upon study design. Reaction vials were incubated under anaerobic
(Argon) conditions. Following 16 hr incubation at 37C, reactions were halted
by the addition of 0.1% (final) formic acid, d4-choline was added as an internal
standard, and then d9- and/or d3-trimethylamine metabolites analyzed by
LC-MS/MS.
Cloning and Expression of yeaW/yeaX
Bioinformatic searching of the E. coli genome for close physically localized
ORFs encoding a potential carnitine transporter, oxygenase/dioxygenase, a
reductase, and malic acid/succinate dehydrogenases consistent with the
known published biochemical pathways identified for carnitine utilization in
Acinetobacter (Ditullio et al., 1994; Englard et al., 1983; Seim et al., 1977,
1982a) was used to identify potential candidate E. coli K-12 DH10B genes,
as further described in the Supplemental Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and two tables and can be found with this article online at
http://dx.doi.org/10.1016/j.cmet.2014.10.006.
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